Fosaprepitant 150 MG Injection — RxCUI 1731077
RxNorm drug concept · Semantic clinical drug
RxCUI 1731077
Semantic clinical drug · SCD
● Current RxNorm concept 24 FDA products
23 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI1731077
Official nameFosaprepitant 150 MG Injection
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asfosaprepitant 150 MG (as fosaprepitant dimeglumine 245.3 MG) Injection
FDA products mapped24
Package NDCs mapped23
Reported Medicaid activity (SDUD)64,775 prescriptions · 51 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Fosaprepitant Dimeglumine: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- It helps prevent nausea and vomiting caused by cancer chemotherapy. You get it along with other anti-nausea medicines. It prevents symptoms but is not studied for treating nausea t...
- A healthcare professional gives it as an IV infusion, usually on the first day of chemotherapy. It finishes about 30 minutes before chemo begins. You will also get a steroid and an...
- Fatigue, diarrhea, low blood counts and weakness are common. Some people have pain or redness at the IV site. Tell your team about any discomfort at the site.
- Tell your nurse immediately if you feel flushed, short of breath, faint or have a rash during or after the infusion. Also report severe pain or swelling where the IV is.
🕸️ Concept Web — How Fosaprepitant 150 MG Injection Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
Fosaprepitant 150 MG Injection
RxCUI 1731077 Semantic clinical drug · SCD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 1
The active substance itself — no strength, form, or brand attached yet.
-
Fosaprepitant
1731071IN
-
Fosaprepitant
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Emend Injection
759503BN
-
Emend Injection
-
Dose forms 6
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Fosaprepitant Injection
1731074SCDF -
Fosaprepitant Injectable Product
1731073SCDG -
Fosaprepitant Injection [Emend Injection]
1731079SBDF -
Emend Injection Injectable Product
1175304SBDG -
Injection
1649574DF -
Injectable Product
1151126DFG
-
Fosaprepitant Injection
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
Fosaprepitant 150 MG
1731076SCDC -
Fosaprepitant 150 MG Injection [Emend Injection]
1731082SBD -
Fosaprepitant 150 MG [Emend Injection]
1731081SBDC
-
Fosaprepitant 150 MG
Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
Fosaprepitant 150 MG
SCDC · 1731076 -
Fosaprepitant Injection
SCDF · 1731074 -
Fosaprepitant Injectable Product
SCDG · 1731073
Brand-Name Concepts
-
Fosaprepitant 150 MG Injection [Emend Injection]
SBD · 1731082 -
Fosaprepitant 150 MG [Emend Injection]
SBDC · 1731081 -
Fosaprepitant Injection [Emend Injection]
SBDF · 1731079 -
Emend Injection Injectable Product
SBDG · 1175304 -
Emend Injection
BN · 759503
📦 FDA Products & Package NDCs
24 products · 23 package NDCs
23 package NDCs map to RxCUI 1731077 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 00006-3061-00 | 1 VIAL, SINGLE-DOSE in 1 CARTON (0006-3061-00) / 5 mL in 1... | EMEND | Merck Sharp & Dohme LLC | 2017-02-03 |
| 00143-9384-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (0143-9384-01) / 5 mL in 1... | FOSAPREPITANT DIMEGLUMINE | Hikma Pharmaceuticals USA Inc. | 2020-09-08 |
| 00143-9428-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (0143-9428-01) / 5 mL in 1... | FOSAPREPITANT DIMEGLUMINE | Hikma Pharmaceuticals USA Inc. | 2021-05-01 |
| 00338-0008-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (0338-0008-01) / 5 mL in 1... | Fosaprepitant | Baxter Healthcare Corporation | 2019-09-05 |
| 00591-4385-79 | 1 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION in 1 CARTON (... | Fosaprepitant | Actavis Pharma, Inc. | 2019-09-19 |
| 16714-0248-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (16714-248-01) / 5 mL in 1... | Fosaprepitant | NorthStar RxLLC | 2023-01-28 |
| 31722-0165-31 | 1 VIAL, SINGLE-DOSE in 1 CARTON (31722-165-31) / 5 mL in 1... | Fosaprepitant | Camber Pharmaceuticals, Inc. | 2021-07-29 |
| 43598-0671-11 | 1 VIAL, SINGLE-DOSE in 1 CARTON (43598-671-11) / 1 INJECTIO... | Fosaprepitant | Dr. Reddy's Laboratories Inc., | 2026-02-12 |
| 43598-0859-11 | 1 VIAL in 1 CARTON (43598-859-11) / 1 mL in 1 VIAL | Fosaprepitant | Dr. Reddy's Laboratories Inc., | 2019-09-06 |
| 43598-0948-11 | 1 VIAL in 1 CARTON (43598-948-11) / 1 mL in 1 VIAL | Fosaprepitant | Dr. Reddy's Laboratories Inc., | 2020-07-01 |
| 55150-0299-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (55150-299-01) / 5 mL in 1... | FOSAPREPITANT DIMEGLUMINE | Eugia US LLC | 2021-01-12 |
| 63323-0972-10 | 1 VIAL, SINGLE-DOSE in 1 CARTON (63323-972-10) / 10 mL in 1... | Fosaprepitant | Fresenius Kabi USA, LLC | 2019-09-05 |
| 67184-0540-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (67184-0540-1) / 5 mL in 1... | FOSAPREPITANT DIMEGLUMINE | Qilu Pharmaceutical Co., Ltd. | 2020-09-08 |
| 67457-0889-10 | 1 VIAL, SINGLE-DOSE in 1 CARTON (67457-889-10) / 5 mL in 1... | fosaprepitant | Mylan Institutional LLC | 2019-09-05 |
| 68001-0523-36 | 1 VIAL, SINGLE-DOSE in 1 CARTON (68001-523-36) / 5 mL in 1... | Fosaprepitant | BluePoint Laboratories | 2022-02-02 |
| 68001-0675-25 | 1 VIAL, SINGLE-DOSE in 1 CARTON (68001-675-25) / 5 mL in 1... | Fosaprepitant | BluePoint Laboratories | 2025-10-15 |
| 71731-5111-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (71731-5111-1) / 5 mL in 1... | FOSAPREPITANT | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 2021-03-16 |
| 71839-0104-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (71839-104-01) / 5 mL in 1... | fosaprepitant | BE Pharmaceuticals Inc. | 2019-10-15 |
| 72162-2636-02 | 1 VIAL, SINGLE-DOSE in 1 CARTON (72162-2636-2) / 5 mL in 1... | Fosaprepitant | Bryant Ranch Prepack | 2026-05-06 |
| 72205-0054-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (72205-054-01) / 5 mL in 1... | Fosaprepitant | Novadoz Pharmaceuticals LLC | 2020-05-12 |
| 72205-0083-01 | 1 VIAL, SINGLE-DOSE in 1 CARTON (72205-083-01) / 5 mL in 1... | Fosaprepitant | Novadoz Pharmaceuticals LLC | 2020-05-12 |
| 83634-0776-10 | 1 VIAL in 1 CARTON (83634-776-10) / 5 mL in 1 VIAL | Fosaprepitant | Avenacy, LLC | 2024-02-28 |
| 83831-0153-01 | 1 VIAL in 1 CARTON (83831-153-01) / 5 mL in 1 VIAL | NAVITRUX | Avyxa Pharma, LLC | 2026-06-24 |
Observed labelers:
Dr. Reddy's Laboratories Inc., (3) ·
BluePoint Laboratories (2) ·
Hikma Pharmaceuticals USA Inc. (2) ·
Novadoz Pharmaceuticals LLC (2) ·
Actavis Pharma, Inc. (1) ·
Avenacy, LLC (1)
· +12 more — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🧾 Billing Codes (HCPCS)
Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
| Code | Descriptor | Mapped packages | Sources |
|---|---|---|---|
| J1453 | Fosaprepitant injection | 15 | CMS |
| J1456 | Inj, fosaprepitant (teva) | 1 | CMS |
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.